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The early stages of Alzheimer’s disease are associ-
ated with synaptic dysfunction prior to overt loss
of neurons. To identify extracellular molecules that
impair synaptic plasticity in the brain, we studied
the secretomes of human iPSC-derived neuronal
models of Alzheimer’s disease. When introduced
into the rat brain, secretomes from human neurons
with either a presenilin-1 mutation, amyloid precur-
sor protein duplication, or trisomy of chromosome
21 all strongly inhibit hippocampal long-term poten-
tiation. Synaptic dysfunction caused by presenilin-1
mutant and amyloid precusor protein duplication se-
cretomes is mediated by Ab peptides, whereas tri-
somy of chromosome 21 (trisomy 21) neuronal secre-
tomes induce dysfunction through extracellular tau.
In all cases, synaptotoxicity is relieved by antibody
blockade of cellular prion protein. These data indi-
cate that human models of Alzheimer’s disease
generate distinct proteins that converge at the level
of cellular prion protein to induce synaptic dysfunc-
tion in vivo.
INTRODUCTION
In Alzheimer’s disease (AD; Table S1 for a full list of abbrevia-
tions), amyloid b-peptides (Ab) and the microtubule-associated
protein tau aggregate and deposit over the course of many de-
cades to produce neuritic plaques and neurofibrillary tangles,
respectively (Hyman et al., 2012). While plaques and tangles
are pathognomonic for AD, current evidence suggests that
soluble extracellular derivatives of amyloid precursor protein
(APP) and tau may be the primary cause of synaptic dysfunction
and cognitive impairment early in the disease (Goedert, 2016;
Spires-Jones and Hyman, 2014).
Deficits in hippocampus-dependent memory are an early
feature of AD, and substantial research has focused on the1932 Cell Reports 23, 1932–1938, May 15, 2018 ª 2018 The Authors
This is an open access article under the CC BY license (http://creativehypothesis that toxic soluble forms of Ab and tau disrupt
hippocampal synaptic memory mechanisms, including long-
term potentiation (LTP) (Spires-Jones and Hyman, 2014;
Sweatt, 2016). Current approaches testing the effects of
Ab and tau at synapses rely on the study of either synthetic
or recombinant proteins (Go´mez-Ramos et al., 2006; Walsh
et al., 2003) and brain- or cerebrospinal fluid (CSF)-derived
material (Fa´ et al., 2016; Lasagna-Reeves et al., 2012; Yang
et al., 2017). While many insights have been gained from
this research, controversy has arisen regarding the disease
relevance of the forms and concentrations of Ab and
tau used (Benilova et al., 2012; Fa´ et al., 2016; Hong et al.,
2018).
Secretomes of induced pluripotent stem cell (iPSC)-derived
neurons carrying causal mutations for AD may better represent
the extracellular environment during the early stages of disease
and, as such, offer the potential to identify proteins that alter
neuronal function (Bright et al., 2015; Goldstein et al., 2015;
Moore et al., 2015). We and others previously reported that
iPSC-derived neurons harboring mutations in APP, preseni-
lin-1 (PS1), or trisomy of chromosome 21 (Ts21) exhibit alter-
ations in APP processing, tau metabolism, and tau release
(Israel et al., 2012; Moore et al., 2015; Muratore et al., 2014;
Shi et al., 2012a; Woodruff et al., 2013; Yagi et al., 2011). To
prospectively identify synaptotoxic proteins generated by
human neurons, we assessed the ability of secretomes from
iPSC-derived models of AD to disrupt LTP when delivered
to the hippocampus of live adult rats. We identify two classes
of secretomes that powerfully disrupt synaptic plasticity via
a common pathway that is mediated by cellular prion
protein (PrP).RESULTS
Inhibition of LTP In Vivo by the Secretomes of Human
Stem Cell Models of AD
Cortical neurons from non-demented control (NDC) and from
three different genetic forms of AD—PSEN1 L113_I114insT
(referred to here as PS1 Int4) (Moore et al., 2015), APP.
commons.org/licenses/by/4.0/).
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Figure 1. Inhibition of LTP In Vivo by Secre-
tomes of Human Stem Cell Models of Alz-
heimer’s Disease
(A) Scheme outlining the generation of cortical
cultures and harvesting of secretomes from
iPSCs.
(B–E) Representative confocal images confirming
the differentiation of cortical neurons from NDC
(B), PS1 Int4 (C), APPDp (D), and Ts21 (E) iPSCs of
each genotype by the expression of TBR1 (red), a
transcription factor expressed in layer 6 gluta-
matergic neurons, and neuron-specific MAP2
(green) in dendrites at day 80 post-neural induc-
tion. Scale bar, 100 mm.
(F) The application of high-frequency conditioning
stimulation (HFS, arrow) in the hippocampal CA1
area of the anesthetized rat induced a robust and
persistent LTP after an intracerebroventricular in-
jection (# inj) of PBS vehicle or NDC secretome
(mean ± SEM % pre-HFS baseline at 3 hr: Veh,
129.7 ± 1.8%; NDC, 123.2 ± 2.3%).
(G) Injection of secretomes from APPDp (103.3 ±
2.6%), PS1 Int4 (105.1 ± 3.4%), or Ts21 (95.7 ±
3.0%) neurons completely inhibited LTP at 3 hr
post-HFS. The y axis is as shown in (F).
(H) Values represent the strength of synaptic
transmission before (Pre) and 3 hr after the appli-
cation of HFS for data in (F) and (G). *p < 0.05, one-
way ANOVA-Sidak and paired t test.
n, number of rats. Calibration bars for EPSP
traces: vertical, 2 mV; horizontal, 10 ms.
See also Figures S1 and S4.duplication (APPDp) (Israel et al., 2012), and Ts21 (Park et al.,
2008)—were generated from iPSCs according to our previously
described methods (Shi et al., 2012b). Secretomes were har-
vested at 48-hr intervals between days 70 and 80 post-neural
induction from cultures of cortical glutamatergic neurons and
astrocytes (Figures 1A–1E; Figures S1A–S1D). As we previ-
ously reported, APPDp and Ts21 cultures secreted more Ab
than NDC neurons (Figure S1E), and PS1 Int4 neurons ex-
hibited altered Ab40:Ab42 and Ab40:Ab38 ratios (Figures S1F
and S1G) (Moore et al., 2015). Cultures generated from each
genotype were confirmed as being cortical in neuronal identity
by immunostaining, gene expression, and western blotting,
with the only notable difference in cellular composition being
an increase in astrocyte number in the Ts21 cultures (Fig-
ure S1). Having validated the neuronal composition of the cul-
tures and primary effects of each mutation on Ab production,
we investigated the effects of secretomes on synaptic LTP in
anesthetized rats.
Synaptic plasticity was measured in the CA1 area of the
dorsal hippocampus following injection of secretomes via a
cannula into the lateral ventricle adjacent to the location of the
implanted stimulating and recording electrodes under urethane
anesthesia. The application of high-frequency conditioning
stimulation (HFS) 30 min after the intracerebroventricular
(i.c.v.) injection of NDC secretome (10 mL) triggered robust
and stable LTP that was indistinguishable from LTP in vehicle-
injected rats (Figures 1F and 1H). In contrast, injection of APPDp,PS1 Int4, and Ts21 secretomes all inhibited LTP (Figures 1G
and 1H).
LTP Inhibition by PS1 Int4 and APPDp Secretomes Is
Mediated by Ab
The LTP-disrupting secretomes have altered levels or composi-
tion of Ab peptides compared with that of NDC neurons (Figures
S1 and S2). Therefore, we tested whether removal of Ab could
prevent LTP inhibition by each secretome. Immunodepletion
(ID) of secretomes was performed with the pan-anti-Ab-antise-
rum AW7, which recognizes multiple Ab sequences and aggre-
gation states but not APPsa or Ah peptides (Hong et al., 2018)
(see Table S2 for a list of antibodies and their antigens/epitopes).
As expected, AW7 ID effectively removed Ab from neuronal se-
cretomes so that neither Ab40 nor Ab42 was detected by ELISA
(Figures 2A and 2B). LTP inhibition by APPDp and PS1 Int4 secre-
tomes was prevented by AW7 ID, confirming that Ab peptides
are responsible for their synaptotoxic effects (Figures 2C
and 2D). However, immunodepletion of Ab peptides did not
alter the LTP inhibition mediated by Ts21 secretome (Figures
2C and 2D).
We used size exclusion chromatography (SEC) to fractionate
all the secretomes and assayed fractions using Ab40 and Ab42
ELISAs and western blotting (Figure S2). Both ELISAs detected
a large Ab monomer peak with negligible amounts of higher-
molecular weight species. The APPDp secretome contained the




Figure 2. LTP Inhibition by PS1 Int4
or APPDp Secretomes Is Prevented by
Immunodepletion with a Pan-Ab Polyclonal
Antibody
(A and B) Neuronal secretomes treated with pre-
immune serum (Mock) contain Ab40 (A) and Ab42
(B) at levels readily detectable with immunoas-
says, whereas AW7 immunodepleted secretomes
do not contain quantifiable levels of Ab.
(C) Immunodepletion of Ab peptides with AW7
rescued the inhibition of LTP by APPDp (APPDp/
AW7: 123.4 ± 3.5%) and PS1 Int4 (PS1 Int4/AW7:
131.8 ± 2.8%), but not Ts21 (Ts21/AW7: 105.1 ±
3.7%). Calibration bars for EPSP traces: vertical,
2 mV; horizontal, 10 ms.
(D) Values before (Pre) and 3 hr post-HFS. The
y axis is as shown in (C). *p < 0.05, one-way
ANOVA-Sidak and paired t test.
See also Figures S2 and S4.Ab42/40 ratio. Otherwise, there were no notable differences be-
tween lines (Figures S2A and S2B). Western blotting with 6E10, a
monoclonal antibody that recognizes Ab, N-terminally extended
(NTE)-Ab, Aha, and APPsa, also failed to reveal differences that
could explain why PS1 Int4 and APPDp secretomes block LTP in
an Ab-dependent manner, whereas the block mediated by Ts21
secretome was independent of Ab (Figure S2C).
Extracellular Tau Mediates the Blockade of LTP by the
Secretome of Ts21 Neurons
Our functional analyses demonstrated that the plasticity-disrupt-
ing activity in APPDp and PS1 Int4 secretomes was mediated by
a form of Ab, whereas the activity in the secretome of Ts21 neu-
rons was mediated by a distinct entity. Certain forms of tau are
known to inhibit LTP (Fa´ et al., 2016; Lasagna-Reeves et al.,
2012), and tau metabolism is altered in both fAD and Ts21 neu-
rons (Hof et al., 1995; Mondrago´n-Rodrı´guez et al., 2014; Porte-
lius et al., 2014). To address the potential involvement of tau, we
immunodepleted the Ts21 secretome that previously had been
immunodepleted of Ab (Ts21/AW7), using a mid-region-directed
anti-tau antibody, Tau5 (Figure S3A). This reduced the most
abundant tau species in the Ts21 secretome by more than
80%, compared with an isotype control antibody (Figure 3A).
Ts21 secretome mock-immunodepleted with the isotype control
antibody impaired LTP, whereas immunodepletion of tau pre-
vented the inhibition of LTP (Figures 3B and 3C).
To further examine whether synaptotoxic forms of tau were
produced by each of the genetic models of AD studied here,
an excess of Tau5 (2.5 mg) was co-injected with each secretome.
Inhibition of LTP by Ts21/AW7 secretome was prevented by co-
injection with Tau5, whereas the anti-Ab antibody 6E10 (used as
an isotype control) had no effect (Figures 3D and 3E). In contrast
to results found with Ts21/AW7 secretome, co-injection of Tau5
did not prevent the inhibition of LTP by APPDp or PS1 Int4 secre-
tomes (Figures 3F and 3G).
To compare the forms of extracellular tau released by neu-
rons of each genotype, we analyzed their secretomes with
four ELISAs, which, in combination, can differentiate between1934 Cell Reports 23, 1932–1938, May 15, 2018full-length (FL), mid-region (MR), N-terminal (NT), and C-termi-
nal (CT) fragments of tau (Figure S3A; Table S3). The relative
distribution of extracellular tau was comparable across lines,
with MR-containing fragments the most prominent (Table S3).
To further resolve different forms of tau, we size-fractionated
secretomes from Ts21 and PS1 Int4, which showed that Ts21
secretome contained more SEC early-eluting MR- and CT-reac-
tive material (Figures S3B–S3E). Although less sensitive than
ELISA, western blotting detected a broad range of tau frag-
ments and allowed resolution of different-sized species that
elute in the same SEC fractions (Figures S3F and S3G). Tau
fragments were more abundant in PS1 Int4 than Ts21 secre-
tomes, with the exception of an 11-kDa band that was at
higher levels in the Ts21 secretome (Figures S3F and S3G,
green boxes).
Independent iPSC Lines Recapitulate the Genotype-
Specific Effects of PS1 Int4 and Ts21 Secretomes
We tested secretomes from neurons differentiated from inde-
pendent non-diseased control (NDC.B), PS1 Int4 (PS1 Int4.B),
and Ts21 (Ts21.B) iPSC lines (Figures S4A–S4D) to investigate
the reproducibility of our findings. PS1 Int4.B iPSCs were
derived from the same donor as in our initial experiments but
were reprogrammed independently using a different method.
Ts21.B iPSCs were generated from a second independent
Ts21 donor. As before, secretomes from healthy control
(NDC.B) neurons did not block LTP induction (Figures S4E
and S4F). In contrast, PS1 Int4.B secretome blocked LTP,
and this activity was relieved by ID of Ab peptides with AW7
(Figures S4G–S4I), as was found with PS1 Int4 (Figure 2). As
with Ts21 secretome (Figure 3), Ts21.B secretome blocked
LTP, and this effect was prevented by tau immunodepletion
(Figures S4J–S4L).
Synaptic Dysfunction Induced by PS1 Int4, APPDp, and
Ts21 Secretomes Is Dependent on Cellular PrP
Given that PrP has been shown to be a mediator of Ab-induced
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Figure 3. Extracellular Tau Mediates the
Blockade of LTP by the Ts21 Secretome
(A) Immunodepletion of Ts21 secretome with Tau5
reduced the levels of mid-region containing tau to
less than 20% of the original concentration. The
monoclonal antibody 46-4 was used as an isotype
control.
(B and C) Tau immunodepletion with Tau5 pre-
vented the inhibition of LTP by the Ts21 secretome
that had previously been immunodepleted with
AW7,whilemock IDwith46-4didnot (B).Dataat3hr
(Ts21/AW7/Tau5: 134.3 ± 7.0%; Ts21/AW7/46-4:
105.2± 4.9%) are summarized in (C). *p< 0.05, two-
way ANOVA RM-Sidak and paired t test.
(D and E) Ts21 secretome that had previously
been immunodepleted with AW7 inhibited LTP
(Ts21/AW7: 106.7 ± 4.9%). Co-injection of Tau5
prevented inhibition of LTP (Ts21/AW7+Tau5:
120.8 ± 2.6%), while an isotype control antibody
(6E10, 2.5 mg, i.c.v. injection) did not (Ts21/
AW7+6E10: 102.9 ± 1.7%), as summarized in (D)
and (E). The y axis is as shown in (D). *p < 0.05,
one-way ANOVA-Sidak and paired t test.
(F and G) Stable LTP was induced by HFS 30 min
after the i.c.v. injection of NDC secretome. Tau5
(2.5 mg, i.c.v. injection) was co-administered with
APPDp secretome but did not affect the inhibition
of LTP (APPDp+Tau5: 107.4 ± 5.4%). LTP was
inhibited to a similar extent in animals treated with
PS1 Int4 secretome (99.2 ± 2.5%) or co-treated
with Tau5 (PS1 Int4+Tau5: 102.4 ± 6.2%), as
summarized in (F) and (G). The y axis is as shown
in (F). *p < 0.05, one-way ANOVA-Sidak and
paired t test.
Calibration bars for EPSP traces: vertical, 2 mV;
horizontal, 10 ms.
See also Figures S3 and S4.suggested to act as a sensor for misfolded proteins (Resen-
berger et al., 2011), we investigated whether PrP was involved
in the plasticity defects induced by neural secretomes. Pre-injec-
tion of 6D11, an antibody known to prevent Ab binding to PrP
(Laure´n et al., 2009), prevented the disruptive effect of PS1
Int4 (Figures 4A and 4B) and APPDp (Figures 4C and 4D) secre-
tomes on LTP. The inhibition of synaptic plasticity by Ts21 secre-
tome was also prevented by 6D11 but not by an isotype control
antibody (Figures 4E and 4F). Furthermore, 6D11 alone did not
facilitate a control decremental LTP induced by a weak condi-
tioning stimulation protocol (Figures 4G and 4H). Together, these
data indicate that, although the synaptotoxic activity of PS1 Int4,
APPDp, and Ts21 secretomes are mediated by distinct proteins,
all require PrP to disrupt plasticity.
DISCUSSION
We report here the use of human iPSC-derived neuronal secre-
tomes and the in vivomeasurement of LTP to search for extracel-
lular factors that impair synaptic plasticity. Impairment of LTP by
APPDp and PS1 Int4 secretomes is mediated by soluble Ab,
whereas the active entity in Ts21 secretome is a soluble form of
tau. The replication of these findings using independent PS1
Int4 and Ts21 secretomes supports the conclusion that severaldifferent synaptoxic proteins are releasedbyhumanstemmodels
of AD.
While the identity and, consequently, the concentration of the
toxic species are currently unknown, we infer from our measure-
ments of Ab and tau that the concentration of active species is
likely to be in the low nanomolar/picomolar range. Immediately
obvious candidates for the active APP-derived synaptotoxic
species in PS1 Int4 and APPDp secretomes include oligomeric
forms of canonical Ab (Lambert et al., 1998) or NTE-Ab (Welzel
et al., 2014), each of which have been shown to perturb LTP
and are recognized by the AW7 antiserum. While we detected
these and various other APP derivatives in the secretomes of
all lines studied, we discerned no obvious qualitative difference
that could explain why only the PS1 Int4 and APPDp secretomes
block LTP in a manner prevented by immunodepletion of Abwith
the AW7 antibody.
Detailed analysis of secretomes using four distinct tau ELISAs,
two different western blotting antibodies, and size fractionation
revealed a complex mixture of extracellular tau species. Consis-
tent with previous reports, we detected abundant mid-region
fragments, lower levels of NT and CT fragments, and very low
amounts of FL tau (Bright et al., 2015; Kanmert et al., 2015).
While there were no obvious qualitative differences between
the forms and levels of tau in Ts21 secretome compared withCell Reports 23, 1932–1938, May 15, 2018 1935
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Figure 4. Synaptic Dysfunction Induced by PS1 Int4, APPDp, and Ts21 Secretomes Can Be Relieved by Targeting Cellular PrP
(A and B) The inhibition of LTP mediated by the PS1 Int4 secretome (104.6 ± 3.3%) was restored to the level of vehicle controls (132.4 ± 7.2%) by i.c.v. pre-
injection (triangle) of 6D11 (6D11+PS1: 129.6 ± 5.3%) (A). Data at 3 hr post-HFS are summarized in (B). The y axis is as shown in (A). *p < 0.05, one-way ANOVA-
Sidak and paired t test.
(C and D) Pre-injection of 6D11 also prevented the inhibition of LTP by the APPDp secretome (C). Data at 3 hr (Veh+APPDp: 105.7 ± 1.1%; 6D11+APPDp: 128.0 ±
3.8%) are summarized in (D). The y axis is as shown in (C). *p < 0.05, two-way ANOVA RM-Sidak and paired t test.
(E and F) The effect of Ts21 secretome (106.7 ± 3.1%) was blocked by 6D11 pre-injection (6D11+Ts21: 127.3 ± 2.9%), but not by an isotype control antibody
(IgG2a+Ts21: 105.8 ± 2.1%), as summarized in (E) and (F). The y axis is as shown in (E). *p < 0.05, one-way ANOVA-Sidak and paired t test.
(G and H) A weak conditioning stimulation protocol (wHFS, arrow) induced a decremental LTP (Veh: 99.8 ± 7.2%), and 6D11 alone (96.4 ± 3.2%) did not facilitate
this decremental LTP, as summarized in (G) and (H). The y axis is as shown in (G). *p < 0.05, two-way ANOVA RM-Sidak and paired t test.
Calibration bars for EPSP traces: vertical, 2 mV; horizontal, 10 ms.the others studied here, we did detect two forms of tau that are
increased in the Ts21 secretome compared with PS1 Int4. One is
a low-abundance fragment that aberrantly elutes from SEC and
lacks an intact N terminus, and the second is a more abundant
11-kDa fragment that spans at least parts of the mid-region
and microtubule-binding-region domains. As yet, it is unclear
why a form of tau is the active species in secretomes from
Ts21, but not PS1 and APPDp lines. Trisomy 21 has complex im-
pacts on cellular biology due to widespread perturbation of the
proteome (Liu et al., 2017), which may contribute to the differ-
ences in extracellular tau production found here.
It has previously been suggested that PrP might serve as a
sensor for protein misfolding and that persistent binding of pro-
tein aggregates may have adverse effects (Resenberger et al.,
2011). Here, we report that plasticity-disrupting activities medi-
ated by extracellular forms of Ab and tau can be prevented by1936 Cell Reports 23, 1932–1938, May 15, 2018antibody blockade of PrP. These results support further investi-
gation of synaptotoxic proteins in the secretomes of iPSC-
derived neurons and the PrP-dependent mechanism by which
they exert their effects. Definitive identification of each synapto-
toxic protein will enable further analysis of the cellular mecha-
nisms underlying their ability to inhibit LTP.
EXPERIMENTAL PROCEDURES
Please see the Supplemental Experimental Procedures and Tables S1 and S2
for full details.
Study Approval
This research was carried out in accordance with the UK Code of Practice for
the Use of Human Stem Cell Lines. The animal care and experimental proto-
cols were carried out in accordance with the approval and oversight of the Irish
Health Products Regulatory Authority, Dublin, Ireland.
Generation of Cortical Cultures and Secretome Collection
Pluripotent stem cells were cultured by standardmethods and differentiated to
cerebral cortex using established protocols (Shi et al., 2012b). Secretomes
were collected at 48-hr intervals between days 70 and 80, after which the
cultures were harvested for RNA and protein analysis or fixed for immuno-
histochemistry. Ab38, Ab40, and Ab42 peptides were analyzed by multiplexed
ELISA.
Secretome Processing and Immunoprecipitation
Secretomes were clarified by centrifugation and dialyzed against artificial
cerebrospinal fluid (aCSF) before freezing at 80C. Immunoprecipitation of
Ab was performed by 2 rounds of 12-hr incubation with AW7 (20 mL) and
Protein A Sepharose beads at 4C. Preimmune serum was used as a control.
Tau5 (10 mg) and Protein G Agarose beads were used in 2 rounds of 12-hr
incubations at 4C to immunodeplete tau. The HIV coat protein 1 antibody,
46-4, was used as a control in tau immunoprecipitations.
SEC, ELISA, and Western Blot
Twelve-milliliter aliquots of ultracentrifuged and dialyzed secretomes were
concentrated 10-fold (to 1.2 mL) using Amicon Ultra-15 3-kDa centrifugal
filters (Millipore, Billerica, MA, USA) at 4C. Immediately thereafter, 1 mL
concentrate was chromatographed on tandemSuperdex 200 Increase-Super-
dex 75 10/300 GL (GE Healthcare, Marlborough, MA, USA) columns eluted in
50 mM ammonium bicarbonate (pH 8.5) (Amersham Life Sciences, Uppsala,
Sweden). One-milliliter fractions were collected and lyophilized for western
blot or used for ELISA analysis.
Electrophysiology
Experiments were carried out on urethane-anesthetized (1.5–1.6 g/kg, intra-
peritoneally [i.p.]) male Lister Hooded rats (250–350 g), with the exception of
28 similarly sized Wistar rats that were used in the initial studies of the LTP
disruptive effect of the Ts21 secretome. Hippocampal LTP was measured
by recording field excitatory postsynaptic potentials (EPSPs) from the stratum
radiatum of CA1 in response to stimulation of the ipsilateral Schaffer collateral/
commissural pathway before and after 200-Hz HFS, as previously described
(Hu et al., 2014). Secretomes were injected via cannula into the lateral ventricle
of rats 30 min before the induction of synaptic plasticity. Tau5 and 6D11 (both
2.5 mg) were co-injected with secretomes, whereas 6D11 and immunoglobulin
G2A (IgG2A) (both 20 mg) were injected 30 min before the application of secre-
tomes to determine the requirement for tau and PrP binding, respectively.
Data Analysis
All statistical analyses of LTP were conducted in Prism v.6.07 (GraphPad
Software, La Jolla, CA, USA). The magnitude of LTP is expressed as the
percentage of pre-HFS baseline EPSP amplitude (±SEM). The n refers to the
number of animals per group. Control experiments were interleaved randomly
throughout. For timeline graphical representation, EPSP amplitudes were
grouped into 5-min epochs; for statistical analysis, EPSP amplitudes were
grouped into 10-min epochs. One-way ANOVA with Sidak’s multiple compar-
ison test (one-way ANOVA-Sidak) was used for comparisons between groups
of three or more. Two-way ANOVA with repeated measures with Sidak’s
multiple comparison test (two-way ANOVA RM-Sidak) was used when there
were only two groups. Paired t tests were carried out to compare pre- and
post-HFS values within groups. A value of p < 0.05 was considered statistically
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.04.040.
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